Laura M. Richards

Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Andrew Barker, Keith H. Gibson, Walter Grundy et al. · Bioorganic & Medicinal Chemistry Letters · 2001 · 559 citations · Full text

Molecular Pharmacology, Drug Targeting, Oncology +10

Fate mapping of human glioblastoma reveals an invariant stem cell hierarchy

Xiaoyang Lan, David J. Jörg, Florence M.G. Cavalli et al. · Nature · 2017 · 408 citations · Full text

Neuro-oncology, Embryonic Stem Cell, Lineage Plasticity +11

Gradient of Developmental and Injury Response transcriptional states defines functional vulnerabilities underpinning glioblastoma heterogeneity

Laura M. Richards, Owen Whitley, Graham MacLeod et al. · Nature Cancer · 2021 · 306 citations

Neuro-oncology, Transcriptional Regulation, Lineage Plasticity +10

Targeting macrophage necroptosis for therapeutic and diagnostic interventions in atherosclerosis

Denuja Karunakaran, Michèle Geoffrion, Lihui Wei et al. · Science Advances · 2016 · 281 citations · Full text

Vascular Disease, Apoptosis, Immunology +21

PRMT5 inhibition disrupts splicing and stemness in glioblastoma

Patty Sachamitr, Jolene Caifeng Ho, Felipe E. Ciamponi et al. · Nature Communications · 2021 · 205 citations · Full text